A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

Sponsor
Sean Liu (Other)
Overall Status
Recruiting
CT.gov ID
NCT05181709
Collaborator
(none)
35
Enrollment
1
Location
7
Arms
16.9
Anticipated Duration (Months)
2.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in healthy adults previously immunized against COVID-19. The IN and IM live virus vaccinations will be identical in composition and only differ in route of administration.

Condition or DiseaseIntervention/TreatmentPhase
  • Drug: Sodium Chloride
  • Biological: NDV-HXP-S IN low dose
  • Biological: NDV-HXP-S IM low dose
  • Biological: NDV-HXP-S IN high dose
  • Biological: NDV-HXP-S IM high dose
Phase 1

Detailed Description

Primary Study Objective: To evaluate the safety and tolerability profile of two dose levels of the NDV-HXP-S vaccine as an IN, IM, or a combined administration IN+IM to healthy, previously immunized adults up to 14 days after administration.

Secondary Study Objective: To evaluate the safety and tolerability profile of two dose levels of the NDV-HXP-S vaccine as an IN, IM, or a combined administration IN+IM to healthy, previously immunized adults up to 365 days after administration.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
35 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Random and Sequential AssignmentRandom and Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Phase-1, Open-Label, Placebo-Controlled Evaluation of a Live, Recombinant Newcastle Disease Virus Expressing the Spike Protein of SARS-CoV-2 (NDV-HXP-S), an Investigational Product for Intranasal (IN) and/or Intramuscular (IM) Vaccination in Healthy Adults Previously Immunized Against COVID-19.
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

ArmIntervention/Treatment
Placebo Comparator: Cohort 1: Placebo / Sodium Chloride

Participants in Cohort 1 will receive placebo given IN+IM in combination. Placebo administration will be given in an ambulatory setting. IN administration will be immediately followed by IM administration. Participants will be monitored by the research staff for 1-hour after administration. Participants will be permitted to receive any additional federally authorized or approved vaccines 56 days after receiving placebo.

Drug: Sodium Chloride
Administered intranasal (IN) and intramuscular (IM) in combination
Other Names:
  • Placebo
  • Active Comparator: Cohort 2: NDV-HXP-S low dose IN

    Participants in Cohort 2 (low, IN) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be admitted to hospital, be given NDV-HXP-S, and then monitored in the hospital for 24 hours post-administration. Upon discharge from the hospital, participants will return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection. A minimum of a 24-hour monitoring period will be spaced between vaccine administrations.

    Biological: NDV-HXP-S IN low dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x108^8 EID50.

    Active Comparator: Cohort 3: NDV-HXP-S low dose IM

    Participants in Cohort 3 (low, IM) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be admitted to hospital, be given NDV-HXP-S, and then monitored in the hospital for 24 hours post-administration. Upon discharge from the hospital, participants will return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection. A minimum of a 24-hour monitoring period will be spaced between vaccine administrations.

    Biological: NDV-HXP-S IM low dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x10^8 EID50.

    Active Comparator: Cohort 4: NDV-HXP-S low dose IN+IM in combination

    Participants in Cohort 4 (low, IN+IM) will receive low doses of NDV-HXP-S at 3.3x108 EID50. Participants will be admitted to hospital and be given NDV-HXP-S where IN and IM doses will be given in succession. They will be monitored in the hospital for 24 hours post-administration. Upon discharge from the hospital, participants will return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection. A minimum of a 24-hour monitoring period will be spaced between vaccine administrations.

    Biological: NDV-HXP-S IN low dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x108^8 EID50.

    Biological: NDV-HXP-S IM low dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x10^8 EID50.

    Active Comparator: Cohort 5: NDV-HXP-S high dose IN

    Participants in Cohort 5 (high, IN) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 5 if Cohort 2 (low dose IN) did not have any SAEs that required additional participants. Participants will be admitted to hospital, be given NDV-HXP-S intranasally, and then be monitored in the hospital for 24 hours post-administration. Upon discharge from the hospital, participants will return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection. A minimum of a 24-hour monitoring period will be spaced between vaccine administrations.

    Biological: NDV-HXP-S IN high dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.

    Active Comparator: Cohort 6: NDV-HXP-S high dose IM

    Participants in Cohort 6 (high, IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 6 if Cohort 3 (low dose IM) did not have any SAEs that required additional participants. Participants will be admitted to hospital, be given NDV-HXP-S intranasally, and then be monitored in the hospital for 24 hours post-administration. Upon discharge from the hospital, participants will return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection. A minimum of a 24-hour monitoring period will be spaced between vaccine administrations.

    Biological: NDV-HXP-S IM high dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.

    Active Comparator: Cohort 7: NDV-HXP-S high dose IN+IM in combination

    Participants in Cohort 7 (high, IN+IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will only enroll into Cohort 7 if Cohort 4 did not have an SAE that required additional participants. Participants will be admitted to hospital, be given IN+IM NDV-HXP-S, and then monitored in the hospital for 24 hours post-administration. Upon discharge from the hospital, participants will return home under home isolation. Home isolation will require daily at-home sample collection and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection. A minimum of a 24-hour monitoring period will be spaced between vaccine administrations.

    Biological: NDV-HXP-S IN high dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.

    Biological: NDV-HXP-S IM high dose
    Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.

    Outcome Measures

    Primary Outcome Measures

    1. Number of local and systemic reactions [14 days]

      The safety and tolerability profile assessed by the number of local and systemic reactions.

    Secondary Outcome Measures

    1. Number of adverse events (AEs) [365 days]

      The safety and tolerability profile assessed by the number of serious adverse events.

    2. Number of serious adverse events (SAEs) [365 days]

      The safety and tolerability profile assessed by the number of serious adverse events.

    3. Number of medically-attended adverse events (MAAEs) [365 days]

      The safety and tolerability profile assessed by the number of medically-attended adverse events (MAAEs).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 59 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Willing and able to provide written informed consent prior to performing study procedures.

    • Males and non-pregnant females who are between 18 to 59 years of age.

    • Asymptomatic, RT-PCR negative (at screening) AND without a known prior history of COVID-19 infection.

    • Provides documentation showing completion of a FDA authorized or approved COVID-19 vaccination regimen, where the last administration was ≥ 6 months (180 days) from the study enrollment date.

    • IF FEMALE PARTICIPANT: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

    • Is not a woman of child-bearing potential (WOCBP); OR

    • Is a WOCBP and using an acceptable contraceptive method during the intervention period (for a minimum of 90 days after NDV-HXP-S vaccination). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. Only highly effective methods of contraception that have a low user dependency or a combination of highly effective methods that are user dependent may be used.

    • IF MALE PARTICIPANT: Agrees to the following requirements during the intervention period and for at least 90 days after NDV-HXP-S vaccination, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s):

    • Refrain from donating sperm AND be abstinent from heterosexual intercourse with a female of childbearing potential as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent; OR

    • Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person. In addition to male condom use, a highly effective method of contraception may be considered in WOCBP partners of male participants.

    • Participant understands and agrees to comply with planned study procedures.

    • Participant agrees to not participate in another clinical trial for treatment of COVID-19 or SARS-CoV-2 through Day 365.

    • Participant agrees to not receive any other vaccination (including COVID-19 vaccine) through Day 56.

    • Provides consent for release of information for hospitalization records and other medically attended visits during the study.

    Exclusion Criteria:
    • Clinical and/or laboratory evidence indicative of COVID-19 infection.

    • Demonstrates a STRONG COVID-19 positive antibody serology (≥ 40 AU/ml) or a NEGATIVE COVID-19 serology on screening.

    • History of hypersensitivity to egg products.

    • History of severe reactions to vaccinations.

    • Potential for prior NDV exposures (i.e., experience as a bird-handler, poultry farmer, or scientist conducting research with NDV).

    • History of an immunocompromising medical condition (such as primary immunodeficiencies, AIDS, or neutropenia).

    • Current or recent use of immunosuppressive medications (i.e. any systemic corticosteroids, chemotherapeutics, immunoglobulin therapies, etc.) based on the assessment of their half-life by the investigator.

    • Any history of HIV, hepatitis C, hepatitis B (by laboratory testing and/or history), Guillain-Barré syndrome, and/or recent receipt of immunoglobulins and/or blood products.

    • Pregnancy or actively breastfeeding.

    • Other medical condition which may place subject at increased risk for harm due to participation in the study as determined by the investigator.

    • In the opinion of the investigator that it would be unwise to allow the participant to be randomized into the study, including those persons who the investigator would consider as high risk of SARS-CoV-2 exposure, including healthcare workers with direct patient care and laboratory workers who handle SARS-CoV-2.

    • Participants at higher risk of severe COVID-19, as defined by CDC guidance (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html). This guidance includes details regarding older adults, people with specific medical conditions, and pregnant and recently pregnant people.

    • Participants with fever or signs of acute infection, including symptoms that could indicate SARS-CoV-2 infection.

    • Participants with a history of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or other nasal abnormality that might affect vaccine administration.

    • Participants who prepare food in the food industry and childcare workers who have direct contact with children 5 years of age or younger.

    • Participants who have close or household high-risk contacts including but not limited to:

    • Persons more than or equal to 65 years of age

    • Children less than or equal to 5 years of age.

    • Residents of nursing homes.

    • Persons of any age with significant chronic medical conditions as well as immunosuppression or cancer.

    • Women who are pregnant, trying to become pregnant, or breastfeeding.

    • Participants who are students, post-doctoral candidates, or trainees of the study site, or are members of the research staff.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Icahn School of Medicine at Mount SinaiNew YorkNew YorkUnited States10029

    Sponsors and Collaborators

    • Sean Liu

    Investigators

    • Principal Investigator: Sean Liu, MD, PhD, Icahn School of Medicine at Mount Sinai

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Sean Liu, Assistant Professor, Icahn School of Medicine at Mount Sinai
    ClinicalTrials.gov Identifier:
    NCT05181709
    Other Study ID Numbers:
    • STUDY-21-01589
    First Posted:
    Jan 6, 2022
    Last Update Posted:
    Apr 5, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Sean Liu, Assistant Professor, Icahn School of Medicine at Mount Sinai
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 5, 2022